SecBot SecBot
8-K ·Filed Nov 5, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 11h ago SEC0001664710-26-000065
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The Takeda license revenue is non-recurring; the core operating loss (R&D + G&A of $27.2M) continues. Monitor the Phase 2 rinvatercept data expected in H1 2027 and the cash burn rate to assess the need for future capital raises.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

KROS drug pipeline →

rinvatercept

● Neutral Named in this 8-K
Impact
Phase
Phase 2
Time to market
Unknown — the drug is in Phase 2 for DMD with initial data expected H1 2027. If successful, Phase 3 trials and regulatory filing would follow, putting potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchWatch for the Phase 2 DMD initial data readout for rinvatercept expected in H1 2027, and any regulatory engagement updates for the ALS program in H2 2026. The stock trades at ~$11.23 with analyst mean price target of ~$19.83 (69% upside), but the stock is 18.8% below its 200-day SMA, reflecting the pre-revenue, binary-risk profile typical of clinical-stage biotechs.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$9.36
T+0 close · Nov 5, 2026 · via day close
Latest settled
+10.04%
T+5 · $10.30 · next T+20 in 20d
Vs SPY
+7.45%
α at T+5
Latest observation
+8.27%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $9.36entry
  2. T+1 · 8d ago −2.03%α −4.40% · $9.17
  3. T+5 · 4d ago +10.04%α +7.45% · $10.30
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Keros Therapeutics reported Q3 2026 net income of $14.2 million, a significant swing from a net loss of $7.3 million in Q3 2025, driven by $40 million in license revenue from Takeda.

Key Financial Metrics

Revenue
$40.0M
est $13.9M · +187.8% · +180.5% YoY

Key Facts

  • Q3 2026 total revenue of $40.0M vs $14.3M in Q3 2025, driven by $40M in license revenue from Takeda
  • GAAP net income of $14.2M vs net loss of $7.3M in Q3 2025
  • Cash and cash equivalents of $259.5M as of Sep 30, 2026, down from $287.4M at Dec 31, 2025
  • Cash runway expected into the second half of 2028
  • First patient dosed in Phase 2 trial of rinvatercept for Duchenne muscular dystrophy in September 2026
  • Nominated KER-206, a nonclinical ligand trap for bone remodeling, for further investigation

Financial Impact

Q3 revenue of $40.0M, GAAP net income of $14.2M, cash burn of ~$28M in the quarter

revenuenet incomecash

Risk Factors

  • Revenue is entirely dependent on the Takeda license agreement and is not recurring
  • Clinical-stage biopharma with no approved products and ongoing operating losses
  • Cash runway only into H2 2028; may require additional financing before then

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001664710-26-000065
Document: kros-20261105.htm0001664710-26-000065
Document: 0001664710-26-000065-index-headers.html0001664710-26-000065
Document: 0001664710-26-000065-index.html0001664710-26-000065
Document: 0001664710-26-000065.txt0001664710-26-000065
8-K Data (Synthetic)0001664710-26-000065

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026